Hylenex

Copyright

All content and images used on this site are owned or licensed by Halozyme, Inc. for use on this site only. Unauthorized use is prohibited.

Terms of Service

Disclaimer

The information on Hylenex.com is provided "as is" without any warranties, expressed or implied. In particular, Halozyme Therapeutics makes no representation or warranty that the information contained on this site will be timely, complete or error-free. To the extent permitted by applicable laws, Halozyme Therapeutics accepts no liability whatsoever in respect of any loss, damage or expenses arising from your use of this site or the unavailability of this site.

Applicable Laws

This site contains information about treatments and therapies, which may or may not be available in all countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information on the Internet. Nothing in this site should be viewed as a solicitation or promotion of any particular treatment or therapy, which is not authorized, by the laws and regulations of the country where the reader resides, or as a promotion or advertisement of any products or services.

Health Information

This site contains information on medical and health-related topics. This information is not meant to be a substitute for the advice provided by physicians or other medical professionals. You should not use this information for diagnosing a health problem or disease but should always consult a physician.

Links to Other Websites

Halozyme Therapeutics can direct you to external websites. Halozyme Therapeutics does not own these sites. Halozyme Therapeutics does not necessarily endorse and is not responsible for the content of any offsite pages or any other sites linked to these sites. Use of linked sites that are not owned or operated by Halozyme Therapeutics is at your own risk and Halozyme Therapeutics will not be liable for any loss, damage or expenses, which you suffer or incur as a result of your use of such sites.

Confidentiality and Security on the Internet

Halozyme Therapeutics has taken measures to ensure the security and confidentiality of any information that you provide to this site. However, the Internet is not an absolutely secure medium, and is not under Halozyme Therapeutics’ control. Use of the Internet is solely at your own risk and is subject to the applicable laws and regulations. For details of the way in which Halozyme Therapeutics deals with information relating to you, please refer to the Privacy Policy.

Variations to These Terms and Conditions

Halozyme Therapeutics may, from time to time, make changes to these terms and conditions. However, you will be informed of such changes by a notice on this site.

Trademarks

Hylenex, the Hylenex logo, and THINK OUTSIDE THE VEIN are trademarks of Halozyme Therapeutics.

Any other brands or trademarks that may appear herein are the property of their respective owners.

Nothing contained herein shall be construed as conferring any license or right under any Halozyme, Inc. patent, copyright or trademark.

Please see Important Safety Information and accompanying package insert for Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

Hylenex recombinant (hyaluronidase human injection) is a tissue modifier indicated as an adjuvant in subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs, and in subcutaneous urography for improving resorption of radiopaque agents.

Important Safety Information

Hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product.
Discontinue Hylenex recombinant (hyaluronidase human injection) if sensitization occurs.
Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
Hyaluronidase should not be used to reduce the swelling of bites or stings.
Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
Hyaluronidase should not be applied directly to the cornea.

The most frequently reported adverse experiences have been local injection site reactions, such as erythema and pain. Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug products.

Patients receiving large doses of salicylates, cortisone, ACTH, estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.

Edema has been reported most frequently in association with subcutaneous fluid administration.

The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. As with all parenteral fluid therapy, use the same precautions for restoring fluid and electrolyte balance. Special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of infusion. When solutions devoid of inorganic electrolytes are given subcutaneously, hypovolemia may occur.